PGP and acute myeloid leukemia: Overexpression of P-gp and BCRP has been associated with poor clinical response and MDR in patients with multiple myeloma, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia, and metastatic breast cancer [18].